Evaluation of pre-analytic heat treatment protocol used in the CDC Nijmegen-Bethesda assay for heat inactivation of extended half-life hemophilia treatment products
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All
i


Evaluation of pre-analytic heat treatment protocol used in the CDC Nijmegen-Bethesda assay for heat inactivation of extended half-life hemophilia treatment products

  • Published Date:

    December 06 2019

  • Source:
    Haemophilia. 26(1):e28-e30
  • Language:
    English
Filetype[PDF-743.73 KB]


No Related Documents.

You May Also Like:

  1. Filetype[PDF - 41.93 KB]
    Personal Author:
    Miller, Connie H.
    Published Date:
    Sep 28 2015
    Source:
    Thromb Res. 136(6):1047-1048.
    File Type:
    Filetype[PDF - 41.93 KB]
    File Type:
    Filetype[PDF - 41.93 KB]
  2. Filetype[PDF - 390.05 KB]
    Personal Author:
    Boylan, B. ; Miller, C. H. ;
    Published Date:
    February 20 2018
    Source:
    Haemophilia. 24(3):487-491
    Description:
    IntroductionThe use of pre-analytical heat treatment (PHT) with the Nijmegen-Bethesda assay (NBA) for inhibitors to factor VIII (FVIII) can remove/des...
    File Type:
    Filetype[PDF - 390.05 KB]
    File Type:
    Filetype[PDF - 390.05 KB]
  3. Filetype[PDF - 690.23 KB]
    Personal Author:
    Miller, C. H.
    Published Date:
    Feb 15 2018
    Source:
    Haemophilia. 24(2):186-197.
    Description:
    Inhibitors are antibodies directed against haemophilia treatment products which interfere with their function. Factor VIII (FVIII) inhibitors in haemo...
    File Type:
    Filetype[PDF - 690.23 KB]
    File Type:
    Filetype[PDF - 690.23 KB]
  4. Filetype[PDF - 66.27 KB]
    Personal Author:
    Sabatino, Denise E. ; Pipe, Steven W. ; ...
    Published Date:
    Jul 2019
    Source:
    Haemophilia. 25(4):575-580
    Description:
    IntroductionThe major complication of protein replacement therapy for haemophilia A is the development of anti-FVIII antibodies or inhibitors that occ...
    File Type:
    Filetype[PDF - 66.27 KB]
    File Type:
    Filetype[PDF - 66.27 KB]
  5. Filetype[PDF - 584.20 KB]
    Personal Author:
    Rampersad, A. G. ; Boylan, B. ; ...
    Published Date:
    Jul 13 2018
    Source:
    Haemophilia. 24(5):807-814
    Description:
    Introduction:Accurate diagnosis of an inhibitor, a neutralizing antibody to infused factor VIII (FVIII), is essential for appropriate management of ha...
    File Type:
    Filetype[PDF - 584.20 KB]
    File Type:
    Filetype[PDF - 584.20 KB]